Partner with the world's largest accelerator of medical technology.

You see the full cohort before anyone else does. Partnership puts your scouting, business development, and R&D teams in direct working contact with companies 12 to 36 months ahead of the point where they hit your standard pipeline, with enough structured exposure to judge fit properly. Your team helps select the cohort, mentors the companies you care about, and builds relationships with founders while there is still room to shape the technology, the indication, and the partnership terms.

Every company in our cohort needs regulatory support, testing, quality systems, design engineering, clinical research, and manufacturing. Partnership positions your team in front of them at the moment those decisions are being made, not after a vendor has already been chosen. You deliver real value through mentorship and workshops, and you build a relationship that follows these companies from first prototype through commercial scale.

Your members are the clinicians who decide whether new technology gets adopted. A specialty track, modeled on our work with the American Society of Plastic Surgeons and AHA Ventures/Studio Red, brings your clinical leadership into the selection and mentorship of companies working in your specialty, gives your members early visibility into what is coming, and positions your society as the place where new technology in your specialty gets validated.

If your mission depends on new technology reaching patients, partnership lets you shape which technologies get built. Sponsor a themed track aligned to your condition area, help select the companies, and put your clinical and patient-community expertise directly into the hands of teams designing around it. Your funding goes to acceleration rather than overhead, and you get a transparent view of what the technology pipeline in your area actually looks like.

Partnership gives federal and state programs a ready-made mechanism for moving funded technologies toward commercialization. We provide the structured curriculum, industry mentorship, and corporate access that grant funding alone cannot buy, plus visibility into a national pipeline of early-stage companies working on priority problems. Our work with the Vantage BARDA Accelerator Network is the model for how this operates at scale.

Early-stage companies routinely design their evidence strategy without a clear read on regulatory expectations, and they pay for it later. Participation through accelerator programming and activities reaches hundreds of companies at the point where their pathway is still changeable, and gives your teams an early view of technologies that will arrive at your door in a few years.

Reimbursement is where promising technology most often stalls. Partnership puts your coverage and evidence teams in front of companies while their clinical and economic evidence plans are still being written, so the studies that get run are the studies that can actually support a coverage decision. You also get early sight of technologies that will affect your cost of care, and a direct channel to influence how they are positioned.

Partnership gives you a say in what gets built, starting with the problems you see every day. Your clinicians, supply chain leaders, and innovation teams help evaluate the cohort, mentor the companies solving problems you recognize, and get early access to technologies before they are broadly available. For systems building their own innovation function, our accelerator gives you a structured pipeline without the cost of running one.

Our selection process screens thousands of applicants down to a cohort, then spends a year pressure-testing regulatory strategy, reimbursement pathway, clinical evidence, and manufacturing readiness. Partnership gives you a de-risked, diligence-ready view of that cohort, direct introductions to founders raising now, and a seat alongside the strategics who represent the most likely exit path. You see the same data our mentors see, not a pitch deck.